REFERENCES
- Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996; 334: 494–500
- Javed M A, Sail MS H, Lingaw S, Alfi A, Lubbard E. Etiology of posterior encephalopathy syndrome. Pak J Med Sci. 2005; 21: 149–154
- Edvinson L, Owman C, Sjoberg N O. Autonomic nerves, mast cells, and amine receptors in human brain vessels: a histochemical and pharmacological study. Brain Res. 1976; 115: 337–393
- Schwartz R B, Mulkern R V, Gudbjartsson H, Jolesz F. Diffusion-weighted MR imaging in hypertensive encephalopathy: clues to pathogenesis. Am J Neuroradiol. 1998; 19: 859–862
- Covarrubias D J, Luetmer P H, Campeau N G. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion weighted MR images. Am J Neuroradiol. 2002; 23: 1038–1048
- Szabo K, Poepel A, Pohlmann-Eden B, et al. Diffusion-weighted and perfusion MRI demonstrates parenchymal changes in complex partial status epilepticus. Brain 2005; 128: 1369–1376
- Ito Y, Arahata Y, Goto Y, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. Am J Neuroradiol. 1998; 19: 415–417
- Yaffe K, Ferreiro D, Barkovich J A, Rowley H. Reversible MRI abnormalities following seizures. Neurology 1995; 45: 104–107
- Shin R K, Stern J W, Janss A J, Hunter J V, Liu G T. Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia. Neurology 2001; 56: 388–391
- Edwards M J, Walker R, Vinnicombe S, et al. Reversible posterior encephalopathy syndrome following CHOP therapy for diffuse large B cell lymphoma. Ann Oncol. 2001; 12: 1327–1329
- Hurwitz R L, Mahoney D H, Armstrong D L, Browder T M. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol. 1988; 16: 216–219
- Quasthoff S, Hartung H P. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002; 249: 9–17
- de Graaf S S, Bloemhof H, Vendrig D E, Uges D R. Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1995; 24: 235–240
- Kaplan R S, Wiernik P H. Neurotoxicity of antineoplastic drugs. Semin Oncol. 1982; 9: 103–130
- Quinn C T, Kamen B A. A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Invest Med. 1996; 44: 522–530
- Rathi B, Azad R K, Vasudha N, Hissaria P, Sawlani V, Gupta R K. i-Asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia. Pediatr Neurosurg. 2002; 37: 203–205
- Jones B V, Egelhoff J C, Patterson R J. Hypertensive encephalopathy in children. Am J Neuroradiol. 1997; 18: 101–106
- Angelo P D, Farruggia P, Bello A L, et al. Reversible posterior leukoencepahalopathy syndrome: report of 2 simultaneous cases in children. J Pediatr Hematol Oncol. 2006; 28: 177–181
- Williams S, Horrocks I A, Ouvrier R A, Gillis J, Ryan M M. Critical illness polyneuropathy and myopathy in pediatric intensive care: a review. Pediatr Crit Care Med. 2007; 8: 18–22
- Greenwood M J, Dodds A J, Garricik R, Rodriguez M. Posterior leukoencephalopathy in association with the tumor lysis syndrome in acute lymphoblastic leukaemia—a case with clinicopathological correlation. Leuk Lymphoma. 2003; 44: 719–721
- Bennett B, Booth T, Quan A. Late onset seizures, hemiparesis and blindness in hemolytic uremic syndrome. Clin Nephrol. 2003; 59: 196–200